PARP1 and myelodysplastic syndrome: Cell proliferation, PARP1/APE1 mRNA expression, and γH2AX foci levels demonstrated no consistent correlation with the cytotoxic efficacy of talazoparib and APE1 inhibitor III in MDS/CMML and AML cells.